GBY Stock Overview
Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Sangamo Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$5.05 |
| 52 Week High | US$9.20 |
| 52 Week Low | US$2.99 |
| Beta | 1.21 |
| 1 Month Change | 0% |
| 3 Month Change | 10.28% |
| 1 Year Change | -47.77% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -2.07% |
Recent News & Updates
Recent updates
Shareholder Returns
| GBY | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | 1.8% | -0.3% |
| 1Y | -47.8% | -19.9% | 2.8% |
Return vs Industry: GBY underperformed the German Biotechs industry which returned -23.4% over the past year.
Return vs Market: GBY underperformed the German Market which returned 4.7% over the past year.
Price Volatility
| GBY volatility | |
|---|---|
| GBY Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 5.2% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.3% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: GBY has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine GBY's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1995 | 431 | Sandy Macrae | www.sangamo.com |
Sangamo Therapeutics, Inc., a clinical-stage biotechnology company, focuses on translating science into genomic medicines that transform patients' lives using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation. The company offers zinc finger protein (ZFP), a technology platform for making zinc finger nucleases, which are proteins used in modifying DNA sequences by adding or knocking out specific genes; and ZFP transcription factors proteins used in increasing or decreasing gene expression. It develops SB-525, which is in Phase III AFFINE clinical trial for the treatment of hemophilia A; ST-920, a gene therapy, which is in Phase I/II STAAR clinical trials for the treatment of Fabry disease; and SAR445136, a cell therapy, which is in Phase I/II PRECIZN-1 clinical trials for the treatment of sickle cell disease.
Sangamo Therapeutics, Inc. Fundamentals Summary
| GBY fundamental statistics | |
|---|---|
| Market cap | €598.47m |
| Earnings (TTM) | -€179.37m |
| Revenue (TTM) | €113.04m |
5.3x
P/S Ratio-3.3x
P/E RatioIs GBY overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GBY income statement (TTM) | |
|---|---|
| Revenue | US$112.06m |
| Cost of Revenue | US$235.52m |
| Gross Profit | -US$123.46m |
| Other Expenses | US$54.34m |
| Earnings | -US$177.80m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.08 |
| Gross Margin | -110.18% |
| Net Profit Margin | -158.67% |
| Debt/Equity Ratio | 0% |
How did GBY perform over the long term?
See historical performance and comparison